Serina Therapeutics Files 8-K
Ticker: SER · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-update, filing
TL;DR
Serina Therapeutics (formerly AgeX) filed an 8-K on 8/25/25. Standard update.
AI Summary
Serina Therapeutics, Inc. filed an 8-K on August 25, 2025, reporting other events and financial statements/exhibits. The company, formerly known as AgeX Therapeutics, Inc. until June 6, 2017, is incorporated in Delaware and headquartered in Huntsville, Alabama.
Why It Matters
This filing indicates Serina Therapeutics is providing updates on its corporate activities and financial status to the SEC, which is standard procedure for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant corporate events or financial updates, and does not inherently signal high risk.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- August 25, 2025 (date) — Date of Report
- AgeX Therapeutics, Inc. (company) — Former Company Name
- June 6, 2017 (date) — Date of Name Change
- Huntsville, Alabama (location) — Principal Executive Offices Location
FAQ
What is the primary purpose of this 8-K filing for Serina Therapeutics, Inc.?
The filing is to report "Other Events" and "Financial Statements and Exhibits" as of August 25, 2025.
When was Serina Therapeutics, Inc. formerly known as AgeX Therapeutics, Inc.?
The company was formerly known as AgeX Therapeutics, Inc. until June 6, 2017.
Where are Serina Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
What is the SEC file number for Serina Therapeutics, Inc.?
The SEC file number for Serina Therapeutics, Inc. is 001-38519.
What is the fiscal year end for Serina Therapeutics, Inc.?
The fiscal year end for Serina Therapeutics, Inc. is December 31.
Filing Stats: 460 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2025-08-25 16:03:43
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate
Filing Documents
- ser-20250825.htm (8-K) — 23KB
- ser-252x505b2xpr003vcleans.htm (EX-99.1) — 15KB
- 0001708599-25-000105.txt ( ) — 162KB
- ser-20250825.xsd (EX-101.SCH) — 2KB
- ser-20250825_lab.xml (EX-101.LAB) — 23KB
- ser-20250825_pre.xml (EX-101.PRE) — 13KB
- ser-20250825_htm.xml (XML) — 3KB
01 Other Items
Item 8.01 Other Items On August 25, 2025, the Company issued a press release announcing that following a recent Type B meeting with the FDA, the Agency's written feedback supports advancing SER-252 (POZ-apomorphine) in a registrational clinical study program in advanced Parkinsons's under the 505(b)(2) NDA pathway. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release announcing the FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: August 25, 2025 By: /s/ Steve Ledger Chief Executive Officer